uploads/2017/12/ONCOLOGY-GROWTH-DRIVERS.png

Eclipse System Expands Varian’s Market Presence in Australia

By

Updated

Overview

On December 12, 2017, Varian Medical Systems (VAR) announced that the Peter MacCallum Cancer Centre (also known as Peter Mac) in Melbourne, Australia, had selected Varian’s Eclipse treatment planning system for the replacement of its existing platform for cancer treatment in all of its sites.

The solution also includes Varian’s Velocity system for information storage and management. The order was accounted for in fiscal 4Q17. Orders in recent fiscal years have seen double-digit growth boosted by the momentum in Varian’s software business.

Varian Medical Systems launched Eclipse 15.5 in September 2017. For details on the launch, read Key Growth Driver: Varian Medical Systems Launched Eclipse 15.5. The company expects Eclipse to be a key driver of its growth going forward.

Competition in the oncology market is triggering some market leaders to accelerate their innovation and expansion strategies in the market. These players include Accuray (ARAY), Becton, Dickinson and Company (BDX), and Boston Scientific (BSX). Investors keen on getting exposure to Varian Medical Systems and its peers can invest in the iShares Dow Jones US Medical Devices ETF (IHI). IHI has ~1.8%, 0.16%, 4.3%, and 5.5% of its total holdings in Varian Medical Systems, Accuray, Boston Scientific, and Becton, Dickinson and Company.

Eclipse software features and capabilities

The physician gives dosage instructions, and Eclipse creates an optimized radiotherapy treatment plan based on the tumor information with respect to the shape, size, and location. Some unique features of the software include MCO (multicriteria optimization) and RapidPlan knowledge-based planning.

MCO enables the exploration of various clinical criteria and their effects on treatment outcome—for instance, targeted tumor coverage versus the degree of radiation exposure to particular organs. RapidPlan helps accelerate and simplify the treatment planning process for advanced cancer treatments that include SRS (stereotactic radiosurgery), IMRT (intensity-modulated radiotherapy), and SBRT (stereotactic body radiotherapy).

Management speaks

According to Chris Cowley, managing director at Varian Australia, “We are proud of our ongoing partnership with Peter Mac and its selection of the Varian solution to provide the most advanced adaptive treatment planning available from anywhere and at any time across the network of their sites. We look forward to collaborating with Peter Mac on the deployment of this solution and together helping create a world without the fear of cancer.”

More From Market Realist